Infective endocarditis (IE) is a severe condition associated with high mortality. Due to the relative low prevalence of IE, prospective data are lacking and current guidelines are mostly based on expert consensus with low level of evidence. IE is also associated with severe complications especially strokes that occur in about one third of the patients.
In order to improve the management and the prognosis of IE, clinical data from larges prospective cohort studies are needed.
Patients with confirmed IE according to European Society of Cardiology criteria
Opposition of the patient to participate
All the patients with IE admitted at Cardiology institute of the Pitié-Salpêtrière hospital
Cohort
Prospective
Not listed
All-cause in hospital mortality
All-cause mortality during the length of hospital stay
All-cause mortality
mortality at longest follow-up
symptomatic or asymptomatic systemic embolism
symptomatic or asymptomatic systemic embolism confirmed by any type of imaging during initial hospitalization
Association between coagulation biomarkers (D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism
Association between coagulation biomarkers (D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism at the admission Initial Hospitalization
Association between coagulation biomarkers (D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism
Association between coagulation biomarkers(D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism within 90 days after admission
Click on the lead sponsor to view all of their trials.
